Correspondence: Mohammed Tag-Adeen. Department of Gastroenterology and Hepatology. Nagasaki University Hospital. 1-7-1 Sakamoto, Nagasaki-Shi. Nagasaki, Japan. e-mail: tagmedicine@gmail.com ABSTRACT Background and aim: pancreatic juice cytology (PJC) is an important predictor of malignant intraductal papillary mucinous neoplasm (IPMN). This study aimed to determine the role of PJC for the prediction of malignant IPMN (intraductal papillary mucinous cancer [IPMC]).
INTRODUCTION
Pancreatic intraductal papillary mucinous neoplasm (IPMN) has a variable malignant potential that ranges from premalignant intraductal lesions to malignant neoplasms with invasive carcinoma. Compared to noninvasive IPMN, invasive cancers have a distinct poorer prognosis, with a fiveyear overall survival rate of 36-70% (1, 2) . IPMN are classified according to the involvement of pancreatic ducts. These include: the main duct (MD-IPMN), which are characterized by segmental or diffuse dilation of the main pancreatic duct (MPD) of > 5 mm without other causes of obstruction; branch duct (BD-IPMN), defined as pancreatic cysts of > 5mm in diameter that communicate with the MPD and a mixed type. The malignancy risk is 62.2%, 24.4%, and 57.6%, respectively (3) . International consensus guidelines (ICG) were formulated in 2006 (4, 5) and were refined in 2012 (3) . However, the overestimation of benign lesions with subsequent unnecessary surgery for patients with benign IPMN is still a major concern of using the ICG 2012.
Pancreatic juice cytology (PJC) is an important factor for detecting malignant IPMN (6) and its importance for the differentiation between benign and malignant IPMNs has been reported (7) (8) (9) . Routine use of PJC is not recommended in the European (10) and American guidelines (11) , whereas it is recommended only for research purposes in the ICG 2012 and the 2017 revision of the guidelines (3, 12) . The aim of this study was to analyze the role of PJC for the prediction of malignant IPMN (IPMC).
PATIENTS AND METHODS
A retrospective review was performed of medical records of patients who underwent surgery due to pancreatic IPMN based on the ICG 2012 criteria at the Nagasaki University Hospital, between January 
Imaging criteria
Criteria obtained via the different preoperative imaging modalities were classified according to the ICG 2012 (3).
Pancreatic juice cytology
Preoperative endoscopic retrograde cholangiopancreatography (ERCP) was performed in order to obtain a clear cytologic evidence before surgery using a duodenoscope (JF 260 V; Olympus ® , Tokyo, Japan). After a successful MPD cannulation and injection of sufficient contrast medium to opacify the MPD and its first order branches, a Tandem XL cannula (Boston Scientific ® , MA, USA) was advanced over a 0.025 guidewire. Pancreatic juice was aspirated using a 20 ml syringe via the cannula after withdrawal of the guidewire. The aspirate was then examined by an expert cytologist who was blind to the clinical and imaging data of the patient on the same day as the ERCP. Pancreatic juice was classified according to the cytology results into class I: completely benign and non-neoplastic epithelium; class II: regenerative or neoplastic epithelium with slight dysplasia; class III: neoplastic epithelium with mild dysplasia corresponding to adenoma; class IV: neoplastic epithelium with moderate dysplasia that was highly suggestive of adenocarcinoma; and class V: unequivocal malignant epithelium corresponding to adenocarcinoma (13) (Fig. 1) .
Study definitions
• Only invasive IPMN was defined as malignant IPMN (14) and indicated as IPMC in this manuscript, whereas benign IPMN and high-grade dysplasia are defined as non-IPMC.
• Positive PJC was defined as PJC class III or greater.
• The exact amount of pancreatic juice to be aspirated was not determined prior to ERCP. However, the acquisition of an adequate amount for cytological examination was considered as a technical success.
• Post-ERCP pancreatitis was defined as a three-fold increase in the serum amylase concentration 24 hours after the procedure, accompanied with obvious abdominal pain (15, 16) .
Ethical clearance
This study adheres to the terms of the latest version of the Declaration of Helsinki for medical research and was approved by the Ethical Committee of the Nagasaki University Hospital in May 2017. Written informed consent was obtained from each patient included in the study.
Statistical analysis
Categorical variables are presented as numbers and percentages; continuous variables, as means and standard deviations; and non-parametric variables, as the median with interquartile range-25 (IQR25) and interquartile range-75 (IQR75). The Chi-square test was used to assess differences between the types of data. The validity of the different IPMC predictors was calculated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy. Univariate and multivariate regression analyses were used to determine significant predictors, and the odds ratio (OR) and 95% confidence intervals (95% CI) were also calculated. The false positive rate (FPR) was calculated as the number of positive test results in non-diseased individuals (non-IPMC). A p-value of < 0.05 was considered as statistically significant. All statistical analyses were performed using JMP ® Pro 13, SAS Institute Inc., Cary, NC, USA.
RESULTS

Validity of the ICG 2012 criteria in all IPMN patients
A total of 52 IPMN patients underwent pancreatic surgery in our center between January 1 st 2012 and December 31 st 2016. Thirteen (25%) were female and the mean age was 70 ± 9 years, the median CEA level was 3 ng/ml (IQRs: 2-5) and the median CA19-9 level was 14.5 U/ml (IQRs: 7.5-26).
Fig. 1. PJC images with different magnification powers. Class I (left column) shows abundant background mucus, regularly arranged nuclei and even inter-nuclear distances. Class III (middle column) shows frequent nuclear irregularities, increased chromatin and variable inter-nuclear distances. Class V (right column) shows markedly disrupted cellular and nuclear arrangement, high N/C ratio and a necrotic background.
Categorical variables are shown in table 1. CT was the most commonly used imaging modality in all patients, the pancreatic head (Ph) was the most common site of IPMN and mixed-IPMN was the most common type.
Post-excisional pathologic examination only confirmed IPMC in 15 patients (29%), while 37 patients (71%) had non-IPMC including: 23 adenomas, one adenoma with Pan IN2, one adenoma with Pan IN1B, ten non-invasive IPMN, one non-invasive IPMN with PanIN2 and PanIN3 and one squamoid cyst. The prevalence of IPMC in the different IPMN subtypes was 36% (4/11), 31% (10/32) and 11% (1/9) in MD, mixed and BD-IPMN, respectively (p = 0.3). ). An MPD diameter of 10 mm or more was detected in 7/15 IPMC and 5/37 of non-IPMC patients with a sensitivity of 47% (CI: 21%-73%), a specificity of 86% (CI: 71%-95%) and an accuracy of 75% (CI: 61%-86%). An abrupt change in the MPD caliber with distal pancreatic atrophy was detected in 4/15 IPMC and 1/37 of non-IPMC patients, with a sensitivity of 27% (CI: 8%-55%), a specificity of 97% (CI: 86%-99%) and an accuracy of 77% (CI: 63%-87%) ( Table 3) .
Validity of PJC
A review of patient data revealed that 33 patients had undergone a preoperative pancreatic juice aspiration during ERCP. There was inadequate aspirate for cytology in four patients (one IPMC and three non-IPMC). All had a solid component within the IPMN (p = 0.02); one case had MPD ≥ 5 mm, three had MPD < 5 mm (p = 0.2), two had BD-IPMN and two had non BD-IPMN (p = 0.1). Table 4 shows the diagnostic validity of complementary PJC in the HRS, WF and no-criteria groups after the exclusion of four patients with inadequate aspirate. In patients with HRS (n = 9; three IPMC and six non-IPMC), sensitivity of PJC was 100%, (CI: 29%-100%), specificity was 67%, (CI: 22%-96%) and accuracy was 78% (CI: 40%-97%). In the WF group (n = 17; six IPMC and eleven non-IPMC), sensitivity of PJC was 50% (CI: 12%-88%), specificity was 82% (CI: 48%-98%) and accuracy was 71% (CI: 44%-90%). PJC was negative in all no-criteria group cases (n = 3; one IPMC and two non-IPMC) with a 0% sensitivity, 100% specificity (CI: 16%-100%) and 67% accuracy (CI: 9%-99%). (Table 5) . Furthermore, accurate PJC results were obtained in 100%, 83% (CI: 36%-99%), 75% (CI: 19%-99%), 75% (CI: 35%-97%), 73% (CI: 39%-94%), 67% (CI: 35%-90%) and 60% (CI: 15%-95%) of patients with jaundice, an enhanced solid component, MPD ≥ 10 mm, a cyst diameter ≥ 30 mm, a non-enhanced mural nodule, MPD of 5-9 mm and an abrupt change of MPD caliber with distal pancreatic atrophy, respectively. Figure 3 shows an example of a 71-year old non-IPMC male patient with a false positive HRS (enhanced solid component) and two false positive WFs (cyst ≥ 30 mm and MPD: 5-9 mm). The PJC was negative, which could exclude an IPMC diagnosis, despite the positive imaging criteria. PJC was a false negative in three patients (four IPMC): one MD-IPMC in an 84-year old patient without any imaging criteria (no-criteria group) and a class I PJC, even though the medical history denoted a distal pancreatectomy ten Significant predictors of IPMC were: MPD ≥ 10 mm with a sensitivity of 47%, specificity of 86%, odds ratio of 5.6 and 95% confidence interval of 1.4-22. An abrupt change in MPD with distal pancreatic atrophy had a sensitivity of 27%, specificity of 97%, odds ratio of 13 and 95% confidence interval of 1.3-129. IPMC: intraductal papillary mucinous cancer; OR: odds ratio; CI: confidence interval; MPD: main pancreatic duct. Complementary PJC has improved sensitivity, specificity and accuracy of HRS to 100%, 67% and 78%, respectively. Specificity and accuracy of WF have also markedly improved to 82% and 71%, respectively. The diagnostic validity of PJC in all patients had a sensitivity of 60%, a specificity of 79% and an accuracy of 72%. IPMC: intraductal papillary mucinous cancer (malignant IPMN); TP: true positive; FN: false negative; TN: true negative; FP: false positive; PPV: positive predictive value; NPV: negative predictive value; HRS: high risk stigmata; WF: worrisome features. *95% confidence interval.
Table 4. Diagnostic validity of complementary PJC in patients with high risk stigmata (HRS group, n = 9), worrisome features (WF group, n = 17) and in patients with neither HRS nor WF (no-criteria group, n = 3)
Patients groups
years ago due to a pancreatic tail MD-IPMC; two mixed-IP-MC lesions in the Ph and the pancreatic body of a 78-year old female in the WF group with class I PJC, and one Ph mixed-IPMC in a 73-year old female in the WF group with class II PJC. Class III PJC (false positive) was detected in four non-IPMC cases, two in the HRS group with mixed-IPMN (one adenoma and one non-invasive IPMN) and two in the WF group with MD-IPMN (one adenoma and one non-invasive IPMN). Post-ERCP pancreatitis was recorded in 21% (7/33) of cases; all cases were mild and discharged after proper medical treatment.
DISCUSSION
An increasing indication for resection in the ICG 2012 has improved its sensitivity and NPV over the ICG 2006 but reduced its specificity and PPV (17) (18) (19) . The validity of ICG 2012 in our center has confirmed the same findings with a high sensitivity (93%) and NPV (75%) and low specificity (8%), PPV (29%) and accuracy (33%). Therefore, high FPR of ICG criteria (27% for HRS and 65% for WF) has led to an overestimation of benign IPMN cases with subsequent pancreatic surgery in 37 (71%) patients. The same finding was reported by Moris and Wallace in 2017 (20) . This study noted the limited validity of the current guidelines, which was mainly attributed to the high false positive rates that incorrectly direct the patient to an unnecessary surgical resection, with the associated comorbidities and secondary effects. In order to overcome the limitations of the current guidelines, many studies have investigated whether adding certain laboratory markers to imaging improves its diagnostic abilities. These markers include CA19-9, CEA, neutrophil/lymphocyte ratio and the platelets/lymphocytes ratio (21) (22) (23) (24) . However, the role of PJC is yet to be confirmed. We conducted this study in order to clarify the value of adding complementary PJC to ICG 2012 imaging criteria to improve its diagnostic validity and reduce the rate of unnecessary surgery in IPMN patients.
Based on our findings in both the HRS and WF groups, a negative PJC result could be helpful in changing the therapeutic decision in 13/17 non-IPMC cases; four in the HRS group and nine in WF. This is associated with a subsequent reduction in unnecessary surgery, from 71% to 50% (surgery could be avoided in 13/26 patients with imaging criteria). However, three IPMC patients with WF might be subjected to further follow up. We do not recommend the use of PJC in patients without any HRS or WF, as all patients in the no-criteria group (three patients) had a negative cytology and IPMC was confirmed in one case. With regard to IPMN subtypes, the accuracy of PJC was higher for IPMC detec- tion in BD and mixed types (100% and 75%, respectively) than in MD-IPMN (40%). However, the difference was not statistically significant.
PJC was investigated in previous studies for the detection of malignant IPMN (9,13), studying IPMN progression (8) and IPMN sub-classification (25) , with a sensitivity for malignant IPMN detection of 54% and 40% and specificity of 99% and 93% in studies (9) and (13), respectively. Both studies were independent of imaging criteria and the study of Kawada et al. (9) was limited to BD-IPMN only. Another study (26) investigated the role of PJC in IPMN without mural nodule (MN), with a sensitivity of 94% for IPMN without MN versus 53% for IPMN with MN.
Secretin was used to enhance pancreatic juice secretion and to increase the diagnostic yield of PJC in the study of Ohtsuka et al. (27) . The sensitivity of HRS was lower, with a higher specificity and lower accuracy than our findings, 58% vs 100%, 94% vs 67%, and 73% vs 78%, respectively. With regard to the WF group, the values obtained were higher than our data, 100% vs 50%, 92% vs 82% and 94% vs 71%, respectively. All non-IPMC patients had a negative cytology in the no-criteria group, with 100% specificity in both studies and a higher accuracy in the Ohtsuka et al. study (27) . The cell block method was used by Sai et al. (28) to improve the diagnostic yield of PJC in BD-IPMN, with a subsequent sensitivity, specificity, PPV and NPV of 92%, 100%, 100%, and 97%, respectively. Moreover, PJC was an attractive research area for the detection of malignant IPMN using CEA concentration (29), K-ras gene mutations (30) , aberrant methylation of tumor-related genes (31), mesothelin mRNA (32) and quantitative reverse transcription-polymerase chain reaction using MUC1 (MUC1 mRNA) (33).
Our study was a retrospective review of a small number of patients with an unequal distribution of the different IPMN subtypes that included only four BD-IPMN, five MD-IPMN and 20 mixed lesions. Post-ERCP pancreatitis was reported in 7/33 PJC patients, which may limit the justification of preoperative ERCP in IPMN cases. Despite the verification bias in our study, as a group of our patients (PJC patients) were subjected to additional tests such as cytologic analysis of pancreatic juice, there was no statistically significant difference in IPMC prevalence between PJC patients and the remaining patients (34% vs 22%, p = 0.3).
CONCLUSION
In conclusion, PJC is a statistically significant and fair IPMC predictor. It may be useful to improve the diagnostic validity and reduce the rate of unnecessary pancreatic surgery, whenever used as complementary test to imaging criteria.
